Theralase Technologies Inc (TLTFF)

[was CUIN2]

"Pending Health Canada approval of the ITA, expected in September 2016, Theralase will immediately commence enrollment of patients into a Phase Ib clinical study in the treatment of NMIBC. The primary outcome measures of the Phase Ib clinical study will be safety and tolerability, with a secondary outcome measure of pharmacokinetics (where the drug accumulates in tissue and how it exits the body) and an exploratory outcome measure of efficacy."

http://finance.yahoo.com/news/theralase-increases-revenue-32-2h2016-225000540.html;_ylc=X1MDMTE5Nzc4NDE4NQRfZXgDMQRfeXJpZANhOXFsYzRkYnM5dW12BGcDZFhWcFpEeHVjejVqT1RNeE1qVXpPUzAyWXpBM0xUTTVaamd0WW1ZM01DMDVNVE5qWm1RMVlUaGtObVk4Wm1sbGJHUStkR3gwTG5ZPQRsYW5nA2VuLVVTBG9yaWdfbGFuZwNlbgRvcmlnX3JlZ2lvbgNVUwRwb3MDMARyZWdpb24DVVMEc3ltYm9sA1RMVC5W?.tsrc=applewf